Member Info for Bella6532

'These results provide evidence that AFX001, through genetic engineering, enhances the immunomodulatory function of MSCs by supplementing the mechanism of CD40L antagonism, overcoming the current limitations of conventional adult tissue-derived MSC therapies.'

And don't forget this excellent news too...

https://www.sciencedirect.com/science/article/abs/pii/S1465324924001221

Perhaps DX needs to get into the FAP PET Scanner Diagnostics business...a walk in PET Scanner center in every town. 😂

BV,,,the Europ[ean Fund was mentioned because it had some significance. It was not named so obviously wants to remain under the radar. If their investment was below 3% then a TR1 does not have to be issued. The investor is responsible for telling Avacta if they have passed a threshold and then Avacta issues a TR1. The fact Avacta mentioned the European Fund means they probably know how much was invested and still have not issued a TR1 and therefore it must be under the 3%. I've had Email exchanges with the FD on this very subject and he has confirmed the process. If said investor decides to continue to buy more shares at these levels, in my experience, TR1's usually get issued once an order is filled not as each threshold is passed. I'm not saying they are buying right now but if it is Novartis they now potentially have access to a lot of the trial data.

And Point Biopharma gets a mention too...

IF Novartis Ventures is the European Fund they will have most likely dictated the placing price and insisted on the likes of CC replacing AS.

'SOFIE granted IND for 18F-FAPI in Phase 2 study

Dulles, VA – November 29, 2022 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has received Investigational New Drug (IND) clearance to proceed with clinical study of [18F]FAPI-74, its lead fluorine-18 labelled Fibroblast Activation Protein Inhibitor (FAPI) product. The study accepted as part of the FDA IND review is for a Phase 2, Multicenter, Single Arm, Open Label, Non-Randomized Study of [18F]FAPI-74 PET in patients with Gastrointestinal Cancers. The cancer types included as part of this study are: gastric cancer, cholangiocarcinoma, hepatocellular carcinoma, pancreatic cancer and colorectal cancer.'

Https://www.nvfund.com/portfolio

Still think the European Fund is far more strategic than some may think...

[18F]FAPI-74 PET is currently in 'clinical development and for investigational use only.'

So the Company developing the new PET scanner is using AVA6000 as a test case...which means Avacta has access to some very new tech to add to their data collection/portfolio...great news.

'These results provide evidence that AFX001, through genetic engineering, enhances the immunomodulatory function of MSCs by supplementing the mechanism of CD40L antagonism, overcoming the current limitations of conventional adult tissue-derived MSC therapies.'

Https://www.sciencedirect.com/science/article/abs/pii/S1465324924001221

Https://www.factmr.com/report/doxorubicin-market

That's why we're not seen by markets as worth much because TX only has 1 product in Phase 1 and DX is still loss making with substantial debt over their heads. Pharma will also be looking on ver cautiously until at least Phase 1 2W full data is published and more importantly FDA gives special approval the PreCision will have a real worth as a carrier/targetting devise for other very toxic chemos. Pharma can licence our PreCision and with Avactas help PreCision+toxic chemo drug can be produced and sold without any further trials once AVA6000 completes Phase 3. Correct me if I'm wrong but AVA6000 will still have to complete all it's trials even though it might in the meantime get special FDA approval for certain situations.

D-Geeman...you would think...but anyo e going inside and receiving inside info can't trade their shares until the news is given to the whole market. So what news? Probably only the news contained in the results. Would they have purchased knowing a change of CEO was in process.

Whatever they were told they thought it was a good bet...our shorter has been around shorting for years and they will have k own that.

D-Geeman...but you couldn't/didn't go inside. II's often take the Inside route before coughing up so they get more info.

BV...I've had several EMail exchanges too with another Board member but all suddenly dried up...

Where is CC based?

Why did II's cough up £m's in the placing just to watch their investments drift away?

Have they all been selling off to drive price down to then buy back in again at a lower level...nah.

And why was the European Fund so significant to get a mention..but not by name.

Just guessing but they may have decided to wait for the scan results before issuing any further news if patients are not experiencing any adverse effects. No news is good news and all that.

GoSushi...Fine...just go to the AGM and ask the question. Simples.